These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 23351578)

  • 1. Wax-matrix extended-release niacin vs inositol hexanicotinate: a comparison of wax-matrix, extended-release niacin to inositol hexanicotinate "no-flush" niacin in persons with mild to moderate dyslipidemia.
    Keenan JM
    J Clin Lipidol; 2013; 7(1):14-23. PubMed ID: 23351578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of a new extended-release formulation of nicotinic acid in Korean adults with mixed dyslipidemia: an 8-week, multicenter, prospective, randomized, double-blind, and placebo-controlled trial.
    Kim SH; Kim MK; Lee HY; Kang HJ; Kim YJ; Park BJ; Kim HS
    Clin Ther; 2011 Oct; 33(10):1357-64. PubMed ID: 21955937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Niacin: chemical forms, bioavailability, and health effects.
    MacKay D; Hathcock J; Guarneri E
    Nutr Rev; 2012 Jun; 70(6):357-66. PubMed ID: 22646128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.
    Karas RH; Kashyap ML; Knopp RH; Keller LH; Bajorunas DR; Davidson MH
    Am J Cardiovasc Drugs; 2008; 8(2):69-81. PubMed ID: 18422390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.
    Maccubbin D; Koren MJ; Davidson M; Gavish D; Pasternak RC; Macdonell G; Mallick M; Sisk CM; Paolini JF; Mitchel Y
    Am J Cardiol; 2009 Jul; 104(1):74-81. PubMed ID: 19576324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
    Maccubbin D; Bays HE; Olsson AG; Elinoff V; Elis A; Mitchel Y; Sirah W; Betteridge A; Reyes R; Yu Q; Kuznetsova O; Sisk CM; Pasternak RC; Paolini JF
    Int J Clin Pract; 2008 Dec; 62(12):1959-70. PubMed ID: 19166443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A clinical trial of oat bran and niacin in the treatment of hyperlipidemia.
    Keenan JM; Wenz JB; Ripsin CM; Huang Z; McCaffrey DJ
    J Fam Pract; 1992 Mar; 34(3):313-9. PubMed ID: 1541958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, tolerance, and efficacy of extended-release niacin monotherapy for treating dyslipidemia risks in persons with chronic tetraplegia: a randomized multicenter controlled trial.
    Nash MS; Lewis JE; Dyson-Hudson TA; Szlachcic Y; Yee F; Mendez AJ; Spungen AM; Bauman WA
    Arch Phys Med Rehabil; 2011 Mar; 92(3):399-410. PubMed ID: 21276961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of colesevelam and niacin on low-density lipoprotein cholesterol and glycemic control in subjects with dyslipidemia and impaired fasting glucose.
    Davidson MH; Rooney M; Pollock E; Drucker J; Choy Y
    J Clin Lipidol; 2013; 7(5):423-32. PubMed ID: 24079283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
    Bays HE; Shah A; Lin J; Sisk CM; Dong Q; Maccubbin D
    Am J Cardiovasc Drugs; 2012 Jun; 12(3):197-206. PubMed ID: 22500948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.
    Fazio S; Guyton JR; Polis AB; Adewale AJ; Tomassini JE; Ryan NW; Tershakovec AM
    Am J Cardiol; 2010 Feb; 105(4):487-94. PubMed ID: 20152243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients.
    Bays HE; Maccubbin D; Meehan AG; Kuznetsova O; Mitchel YB; Paolini JF
    Clin Ther; 2009 Jan; 31(1):115-22. PubMed ID: 19243712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of efficacy and safety of fixed dose lovastatin and niacin(ER) combination in asian Indian dyslipidemic patients: a multicentric study.
    Sharma M; Sharma DR; Singh V; Panwar RB; Hira HS; Mohan B; Kumar N; Sharma SK; Gupta R
    Vasc Health Risk Manag; 2006; 2(1):87-93. PubMed ID: 17319473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups.
    Bays H; Shah A; Dong Q; McCrary Sisk C; Maccubbin D
    Int J Clin Pract; 2011 Apr; 65(4):436-45. PubMed ID: 21401833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I.
    Superko HR; McGovern ME; Raul E; Garrett B
    Am J Cardiol; 2004 Sep; 94(5):588-94. PubMed ID: 15342288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome.
    Bays HE; Shah A; Lin J; McCrary Sisk C; Paolini JF; Maccubbin D
    J Clin Lipidol; 2010; 4(6):515-21. PubMed ID: 21122699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
    Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial.
    Illingworth DR; Stein EA; Mitchel YB; Dujovne CA; Frost PH; Knopp RH; Tun P; Zupkis RV; Greguski RA
    Arch Intern Med; 1994 Jul; 154(14):1586-95. PubMed ID: 8031206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients.
    Morgan JM; Capuzzi DM; Guyton JR
    Am J Cardiol; 1998 Dec; 82(12A):29U-34U; discussion 39U-41U. PubMed ID: 9915660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended-release niacin with laropiprant : a review on efficacy, clinical effectiveness and safety.
    Yadav R; France M; Younis N; Hama S; Ammori BJ; Kwok S; Soran H
    Expert Opin Pharmacother; 2012 Jun; 13(9):1345-62. PubMed ID: 22607011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.